Editas medicine stock price.
The analyst also gave the stock a price target of $20. Editas Medicine's share price as of the closing of business day yesterday was $40.98. And even after today's sell-off, Editas Medicine stock ...
Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.Nov 9, 2023 · Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 17.81% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $9.06 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $13.94 and as low as $6.08. Year to date, Editas ... The average Editas Medicine stock forecast 2024 represents a 3.79% increase from the last price of $10.5299997329712. For Editas Medicine stock forecast for 2025, 12 predictions are offered for each month of 2025 with average Editas Medicine stock forecast of $10.98, a high forecast of $12.02, and a low forecast of $10.15.The Editas Medicine stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
What happened. Shares of Editas Medicine ( EDIT 2.28%) were up 13.9% this week as of the market close on Thursday. Most of this big gain came after a key announcement from the company on Wednesday ...Aug 23, 2023 · The average price targets for Editas Medicine and Intellia Therapeutics are $13.18 and $83.75, respectively, according to Yahoo! Finance. That implies an upside of about 54% for the former and 119 ... Gene editing stocks rallied Thursday as Wall Street took notice of the underperforming subsector issuing a series of bullish views despite recent selloff. Read more here.
Nov 21, 2023 · Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 51.5% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $11.14 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $11.93 and as low as $6.08. Year to date, Editas ...
Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 3.99% so far this month. During the month of August, Editas Medicine Inc’s stock price has reached a high of $9.52 and a low of $8.39. Over the last year, Editas Medicine Inc has hit prices as high as $19.97 and as low as $6.33. Year to date, Editas ...Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 8.55% so far this month. During the month of April, Editas Medicine Inc’s stock price has reached a high of $7.21 and a low of $6.45. Over the last year, Editas Medicine Inc has hit prices as high as $20.04 and as low as $6.70. Year to date, Editas ...12 Wall Street analysts have issued 1-year price objectives for Editas Medicine's stock. Their EDIT share price targets range from $7.00 to $30.00. On average, they expect the company's share price to reach $13.92 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price.
The Editas Medicine stock forecast for tomorrow is $ 10.59, which would represent a 0.59% gain compared to the current price. In the next week, the price of EDIT is expected to decrease by -23.77% and hit $ 8.03. As far as the long-term Editas Medicine stock forecast is concerned, here’s what our predictions are currently suggesting.
Mar 27, 2023 · Editas Medicine's cash burn of US$181m is about 36% of its US$503m market capitalisation. That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's ...
Price as of November 22, 2023, 11:14 a.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...A cough can be annoying, and it can affect you day and night. There are many cough medicines available over-the-counter but it’s hard to know which one is the best to alleviate your symptoms. This article will help break down the best over-...Current Price. $10.58. ... Editas Medicine ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street ...Editas Medicine Inc. historical stock charts and prices, analyst ratings, financials, and today’s real-time EDIT stock price.On average, Wall Street analysts predict. that Editas Medicine's share price could reach $14.00 by Oct 24, 2024. The average Editas Medicine stock price prediction forecasts a potential upside of 31.95% from the current EDIT share price of $10.61 .
Over the last month the Editas Medicine, Inc. (NASDAQ:EDIT) has been much stronger than before, rebounding by 72%.Meanwhile over the last three years the …Editas Medicine (EDIT) Stock Price Performance. Editas Medicine (EDIT) Stock Key Data. ... Consensus Price Target is the stock price analysts expect to see within a …View the latest Editas Medicine Inc. (EDIT) stock price, news, historical charts, analyst ratings and financial information from WSJ. Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Editas Medicine Inc’s Stock Price as of Market Close. As of May 16, 2023, 4:00 PM CST, Editas Medicine Inc’s stock price was $9.55. Editas Medicine Inc is down 4.6% from its previous closing price of $10.01. During the last market session, Editas Medicine Inc’s stock traded between $9.58 and $10.51. Currently, there are 68.92 …
Price is a widely used stock evaluation measure. Find the latest Price for Editas Medicine (EDIT) ... Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates 11/03/23-7:45AM EST ZacksEditas Medicine. Market Cap. $860M. Today's Change. (-0.75%) -$0.08. Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may ...
This might seem like deja vu. Editas Medicine ( EDIT 11.39%) shares soared on Monday. Then on Tuesday. And on Wednesday. The stock is on fire again today, skyrocketing 22.3% as of 11:09 a.m. EST ...Editas Medicine, Inc. (EDIT) Stock Price, Quote, News & Analysis EDIT Editas Medicine, Inc. Stock Price & Overview 38.49K followers $10.53 -0.08 ( -0.75%) …Get Editas Medicine Inc (EDIT.OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments ... Price To Sales (TTM) 26.58. Price To Book ...Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to …They need the money for the next leg of the journey, and their stock price is as good as it'll likely get until more data comes out. Take Editas Medicine (EDIT 2.28%) as an example. On June 9, it ...
What was the 52-week low for Editas Medicine stock? The low in the last 52 weeks of Editas Medicine stock was 6.08. According to the current price, Editas Medicine is 174.67% away from the 52-week ...
Editas Medicine, Inc. (EDIT) Stock Forecast & Price Targets - Stock Analysis NASDAQ: EDIT · IEX Real-Time Price · USD Add to Watchlist 10.75 +0.22 …
Editas Medicine, Inc. (EDIT.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Editas Medicine, Inc. | Nasdaq: EDIT | Nasdaq …Funding, Valuation & Revenue. Editas Medicine has raised $163M over 5 rounds. Editas Medicine's latest funding round was a IPO for $94.4M on February 3, 2016. Editas Medicine's valuation in August 2015 was $315.85M. Editas Medicine's latest post-money valuation is from February 2016.Price as of December 1, 2023, 4:00 p.m. ET ... Shares of Editas Medicine (EDIT 2.28%) are sliding today, down by 7.2% as of 11:26 a.m. ET. The decline came after the company announced a big shake ...Editas Medicine stock quote and company news. Get the latest EDIT company stock news & quotes.The Motley Fool has positions in and recommends Beam Therapeutics, CRISPR Therapeutics, Caribou Biosciences, Editas Medicine, Intellia Therapeutics, and Vertex …Price as of December 1, 2023, 4:00 p.m. ET ... This fact has led to a stomach-churning level of volatility among stocks tied to CRISPR and related forms of gene ... Editas …Nov 24, 2023 · What is the target price for Editas Medicine (EDIT) stock? A. The latest price target for . Editas Medicine (NASDAQ: EDIT) was reported by Citigroup on Tuesday, October 24, 2023. Current Price. $10.46. Price as of November 22, 2023, 11:14 a.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Editas Medicine, Inc. (EDIT) is a clinical-stage genome editing company that develops treatments for cancer and other diseases. The stock price, news, quote and history of EDIT are shown on Yahoo Finance. See the latest performance outlook, earnings date, dividend yield, fair value and more.Editas Medicine, Inc. analysts consensus, targets, ratings and recommendations | Nasdaq: EDIT | Nasdaq ... RBC Capital Adjusts Editas Medicine Price Target to $7 From $10, Maintains Sector Perform - Speculative Risk Rating ... Stock Editas Medicine, Inc. - Nasdaq . Consensus Editas Medicine, Inc. CATEGORIES. Indexes; …
Current Price. $10.46. Price as of November 22, 2023, 11:14 a.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Here are three top biotech stocks with major catalysts in December. Editas Medicine ( EDIT ): EDIT will release key clinical data on its sickle cell treatment on Dec. …Mar 27, 2023 · Editas Medicine's cash burn of US$181m is about 36% of its US$503m market capitalisation. That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's ... Aug 23, 2023 · The average price targets for Editas Medicine and Intellia Therapeutics are $13.18 and $83.75, respectively, according to Yahoo! Finance. That implies an upside of about 54% for the former and 119 ... Instagram:https://instagram. best washington state health plansbest books to learn options tradingimproving presentation skills courseswhitneyhancock Nov 17, 2023 · Get Editas Medicine Inc (EDIT.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments how to grow hydroponic cannabischarles mizrahi North American Morning Briefing : Stock Futures, -2- Oct. 02: DJ Stifel Upgrades Editas Medicine to Buy From Hold, Adjusts Price Target to $17 From $9 ... Chardan Cuts Price Target on Editas Medicine to $19 From $22, Maintains Buy Rating Aug. 03: MT Transcript : Editas Medicine, Inc., Q2 2023 Earnings Call, Aug 02, 2023 …Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. is botox for tmj covered by insurance 3 Nov 2023 ... ... Editas Medicine's financial status. The company holds a market cap of 684.13M USD, reflecting its size in terms of market value. The price ...Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.